ASCO Highlights

Professor Everett E. Vokes Discusses His Hopes and Aims as ASCO President

We were delighted to catch up with Prof Everett E. Vokes (University of Chicago Medicine and Biological Sciences, Chicago, IL, USA) to discuss his aims during his 4-year tenure as president of the American Society of Clinical Oncology (ASCO). Question What do you hope to achieve during your tenure as ASCO President? Speaker Disclosure: Everett […]

Head and Neck Cancer

Ian Chau, ASCO 2021: First Results of the Phase III CheckMate 648 Trial

Dr Ian Chau (Royal Marsden Hospital, London, UK) joins us at ASCO 2021 to discuss the pivotal first results of the global phase III CheckMate 648 trial, which revealed first-line nivolumab regimens improve survival in esophageal squamous cell carcinoma. The abstract (LBA4001) ‘Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line […]

Conference Highlights

Shaji Kumar, ASCO 2021: Why Healthcare Professionals Should Visit touchONCOLOGY

touchREVIEWS in Oncology & Haematology Editor in Chief Shaji Kumar discusses his highlights of the ASCO 2021 conference, the need for good medical education and what our platform touchONCOLOGY provides for healthcare professionals. Questions 1. What are the hot topics and new research you’re most interested in from ASCO 2021? (00:20-02:14) 2. What makes for […]

Multiple Myeloma

Shaji Kumar, ASCO 2021: The EQUATE Trial, a Quadruplet Regimen for Multiple Myeloma

We were delighted to talk with Dr Shaji Kumar (Mayo Clinic, Rochester, MN, USA) about the EQUATE trial, developing a quadruplet regimen for newly-diagnosed multiple myeloma, including bortezomib, lenalidomide, dexamethasone and daratumumab. The abstract ‘ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended […]

Haematological Malignancies

Efstathios Kastritis, ASCO 2021: Results from the Phase 3 ANDROMEDA Study

touchONCOLOGY joins Dr Efstathios Kastritis (Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece) at ASCO 2021 to discuss the updated results from the phase 3 ANDROMEDA study. The abstract ‘Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results […]

Colorectal Cancer

Elena Garralda, ASCO 2021: Favezelimab in Metastatic Colorectal Cancer

touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer. The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO […]

Immunotherapy

Omid Hamid, ASCO 2021: Nemvaleukin Alfa and the ARTISTRY-2 Trial

touchONCOLOGY joins Dr Omid Hamid (Chief, Translational Research and Immunotherapy, Director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, Los Angeles, CA, USA) at ASCO 2021 to discuss nemvaleukin alfa and the ARTISTRY-2 trial. The abstract ‘Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2’ (NCT03861793) (abstract number 2552) was presented […]

Bladder Cancer

Stephen B Williams, ASCO 2021: TAR-200 in Combination with Cetrelimab in Muscle-invasive Urothelial Carcinoma of the Bladder

touchONCOLOGY joins Professor Stephen B Williams (Chief, Division of Urology, Professor of Urology and Radiology, Division of Urology, The University of Texas Medical Branch, Galveston, TX, USA) at ASCO 2021 to discuss the efficacy of TAR-200 in combination with cetrelimab in participants with muscle-invasive urothelial carcinoma of the bladder. The abstract ‘A phase 3, multicenter, […]

Gastric Cancer

Yelena Y Janjigian, ASCO 2021: Durvalumab in Gastric Cancer and the MATTERHORN Study

touchONCOLOGY joins Dr Yelena Janjigian (Medical Oncologist, Chief, Memorial Sloan Kettering Cancer Center, New York, NY, USA) at ASCO 2021 to discuss durvalumab in gastric cancer and the MATTERHORN study. The abstract ‘A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer […]

FILTER YOUR SEARCH

Speciality: